The Implementation of Clinical Genomics: Ethical, Societal and Regulatory Considerations by Lyon,  Gholson J.
The	  Implementa,on	  of	  Clinical	  Genomics:	  
Ethical,	  Societal	  and	  Regulatory	  Considera,ons	  
	  
Gholson	  J.	  Lyon,	  M.D.	  Ph.D.	  
	  
@GholsonLyon	  
Conﬂicts	  of	  Interest	  
	  
•  I	  do	  not	  accept	  salary	  from	  anyone	  other	  than	  
my	  current	  employer,	  CSHL.	  
	  
•  Any	  revenue	  that	  I	  earn	  from	  providing	  medical	  
care	  is	  donated	  to	  UFBR	  for	  gene,cs	  research.	  
•  I	  worked	  on	  the	  Clarity	  Challenge	  as	  an	  unpaid	  
medical	  consultant	  to:	  	  
  
Martin Reese, PhD 
President and CEO 
2200 Powell St., Suite 525 
Emeryville, CA 94608 
           
September 30th, 2012 
 
CLARITY Organizers 
Harvard Medical School 
 
Dear CLARITY committee, 
 
On behalf of the Omicia/University of Utah/InVitae, (OUI) team, we would like to 
describe our approach to this challenge, our workflow and reports. We have provided an 
executive summary and a detailed report for each family. The executive summary 
includes the findings and clinical recommendations. The detailed reports show the data 
for each test with supporting evidence and some technical interpretation. In this 
document we provide an overview of our team and our analysis strategy.  
 
Our team is composed of three groups: one academic and two commercial. The OUI team 
includes physicians, geneticists, bioinformaticians, computational biologists, and 
software engineers. Two systems have been at the core of our analyses: The Omicia 
OpalTM platform and the InVitae genetic test of known inherited conditions powered by 
LocusDev. Both tools have been central to our analyses, and we have generated clinical 
laboratory-like reports from both systems. The data provided by the organizers have been 
used as is assuming that the variants are all called correctly. As you can see in the Opal 
report, we have tried to assess the data quality, but only at a very high level, given that 
data generation and variant calling has been out of our control, so a detailed sensitivity 
and specificity analysis was not possible. 
 
Opal is a clinical decision support tool that assists in the clinical interpretation of 
genomes and empowers clinical diagnostics by allowing users to identify a very short list 
of candidate disease-genes and variants of relevance to the disease and phenotype of the 
patient. Opal accomplishes this by automatically embedding the contents of patient 
variant files in a rich analysis environment, providing links to additional genome 
annotations, clinical variants from well-established pathogenic variant databases such as 
OMIM and HGMD, and literature cross-references for candidate disease genes and 
variants, and other resources. Most of the interactive analysis and result inspection has 
been performed with Opal, which is a web application system. Data and analyses were 
securely stored, accessed, shared and discussed by the team during the analysis of the 
project, while each team member had a secure, user controlled access to the genome and 
the analyses results and was able to share their results online. 
 
In summary, our analysis strategy was four-pronged: 
 
Test 1. Genome-wide ab initio searches using VAAST. VAAST is a new-in-class, rapid 
probabilistic search tool for identifying damaged genes and their disease-causing variants 
in personal genome sequences, using population data and amino acid substitution 
•  Twee,ng	  about	  my	  talk	  is	  ok,	  but	  please	  do	  
not	  take	  photographs	  of	  the	  various	  people	  
pictured	  in	  this	  presenta,on.	  They	  have	  given	  
me	  permission	  to	  show	  their	  photos,	  but	  I	  do	  
not	  want	  to	  widely	  distribute	  these	  photos.	  

Proving	  Causality	  	  
 Need	  to	  ﬁnd	  the	  EXACT	  same	  muta,on	  in	  another	  unrelated	  family,	  i.e.	  in	  a	  
diﬀerent	  gene,c	  background	  and	  environment.	  
	  
 How	  did	  we	  ﬁnd	  the	  second	  family?	  
II-1 III-2 
Ogden Syndrome, in honor of where the first family 
lives, in Ogden, Utah 
Many	  barriers	  in	  the	  way	  of	  CLIA-­‐cer,ﬁed	  
gene,c	  tes,ng	  for	  anyone	  to	  use.	  
	  
Mother	  four	  months	  pregnant	  Nov	  2010	  
	  
Baby	  born	  March	  2011.	  
	  
Aﬀected	  with	  Disease.	  
	  
He	  died	  June	  2011,	  same	  week	  as	  
publica,on	  of	  our	  paper	  in	  AJHG.	  
	  
	  
In	  Choosing	  a	  Sperm	  Donor,	  a	  Roll	  of	  the	  Gene,c	  Dice	  
Sarah	  Phipps	  for	  The	  New	  York	  Times	  
	  
Jaxon	  Kretchmar,	  2,	  who	  was	  conceived	  with	  donated	  sperm,	  has	  cys,c	  ﬁbrosis.	  
	  
Whole	  Genome	  Sequencing	  in	  centralized	  
facili,es	  is	  a	  “Disrup,ve	  Technology”	  	  
•  This	  is	  only	  true	  with	  economy	  of	  scale,	  done	  
well	  and	  with	  CLIA	  cer,ﬁca,on.	  	  
•  It	  can	  and	  should	  replace	  single	  gene	  
diagnos,c	  tests	  for	  pa,ents	  presen,ng	  with	  
severe	  gene,c	  illnesses,	  which	  can	  themselves	  
each	  cost	  $3000.	  
•  	  Some,mes,	  physicians	  spend	  
$30,000-­‐100,000	  on	  diagnos,c	  odysseys	  with	  
numerous	  single	  gene	  tests.	  
Pandora’s	  Baby	  
•  “It	  seemed	  to	  boil	  down	  to	  a	  struggle	  between	  
two	  compe,ng	  impulses:	  the	  crea,ve	  drive	  to	  
understand	  nature	  versus	  the	  conserva,ve	  
drive	  to	  impose	  limits	  and	  maintain	  the	  status	  
quo.”	  
Beyond	  our	  Kuhnian	  inheritance	  
A	  recent	  lecture	  by	  Prof	  Greg	  Radick	  ques,ons	  our	  scien,ﬁc	  inheritance,	  
through	  textbook	  histories	  of	  gene,cs	  and	  Thomas	  Kuhn's	  legacy	  
hcp://www.guardian.co.uk/science/the-­‐h-­‐word/2012/aug/28/thomas-­‐
kuhn	  
Walter	  Frank	  Raphael	  Weldon	  
Vs.	  	  
William	  Bateson	  
Forthcoming	  by	  Greg	  Radick.	  Scholarly	  edi,on	  of	  W.	  F.	  R.	  Weldon's	  Theory	  of	  
Inheritance	  (1904-­‐1905),	  coedited	  with	  Annie	  Jamieson.	  
Mendel’s laws of alternative inheritance in peas 29 
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Barbara	  McClintock	  was	  also	  the	  ﬁrst	  scien,st	  to	  
correctly	  speculate	  on	  the	  basic	  concept	  of	  
epigene,cs—and	  she	  did	  so	  before	  the	  
molecular	  structure	  of	  DNA	  was	  even	  discovered.	  
Mainly,	  she	  recognized	  that	  genes	  can	  be	  expressed	  
and	  silenced	  during	  mitosis	  in	  gene,cally	  iden,cal	  
cells.	  Thus,	  in	  these	  few	  sentences,	  McClintock	  
summarized	  epigene,c	  regula,on	  by	  way	  of	  
chroma,n	  remodeling,	  a	  concept	  not	  formally	  
described	  un,l	  more	  than	  40	  years	  later.	  
	   	  
Barbara	  McClintock	  and	  the	  Discovery	  of	  Jumping	  Genes	  (Transposons)	  
Cita,on:	  Pray,	  L.	  &	  Zhaurova,	  K.	  (2008)	  Barbara	  McClintock	  and	  the	  discovery	  of	  jumping	  genes	  (transposons).	  
Nature	  Educa,on	  1(1)	  
Waddington	  claimed	  that	  canals	  form	  in	  the	  epigene=c	  
landscape	  during	  evolu=on,	  and	  that	  this	  heuris=c	  is	  useful	  for	  
understanding	  the	  unique	  quali=es	  of	  biological	  robustness.	  
The	  canalisa,on	  metaphor	  suggests	  that	  phenotypes	  are	  very	  robust	  to	  small	  perturba,ons,	  
for	  which	  development	  does	  not	  exit	  the	  canal,	  and	  rapidly	  returns	  back	  down,	  with	  licle	  
eﬀect	  on	  the	  ﬁnal	  outcome	  of	  development.	  But	  perturba,ons	  whose	  magnitude	  exceeds	  a	  
certain	  threshold	  will	  break	  out	  of	  the	  canal,	  moving	  the	  developmental	  process	  into	  
uncharted	  territory.	  Strong	  robustness	  up	  to	  a	  limit,	  with	  licle	  robustness	  beyond,	  is	  a	  pacern	  
that	  could	  increase	  evolvability	  in	  a	  ﬂuctua,ng	  environment.	  
E.	  coli	  adap,ng	  to	  low	  glucose	  condi,ons,	  in	  the	  context	  of	  media	  containing	  citrate.	  
"Finally,	  novel	  func,ons	  oqen	  emerge	  in	  rudimentary	  forms	  that	  must	  be	  reﬁned	  to	  
exploit	  the	  ecological	  opportuni,es.	  This	  three-­‐step	  process	  —	  in	  which	  poten,a,on	  
makes	  a	  trait	  possible,	  actualiza,on	  makes	  the	  trait	  manifest,	  and	  reﬁnement	  makes	  
it	  eﬀec,ve	  —	  is	  probably	  typical	  of	  many	  new	  func,ons.”	  -­‐	  Lemski	  
Genomic	  analysis	  of	  a	  key	  innova,on	  in	  an	  experimental	  Escherichia	  coli	  popula,on.	  
Blount	  ZD,	  Barrick	  JE,	  Davidson	  CJ,	  Lenski	  RE.	  
Nature.	  2012	  Sep	  19.	  doi:	  10.1038/nature11514	  
	  
Penetrance	  Issues	  
•  We	  do	  not	  really	  know	  the	  penetrance	  of	  	  precy	  much	  
ALL	  muta,ons	  in	  humans,	  as	  we	  have	  not	  
systema,cally	  sequenced	  or	  karyotyped	  any	  gene,c	  
altera,on	  in	  Thousands	  to	  Millions	  of	  randomly	  
selected	  people,	  nor	  categorized	  into	  ethnic	  classes,	  
i.e.	  clans.	  
•  There	  is	  a	  MAJOR	  clash	  of	  world-­‐views,	  i.e.	  do	  single	  
muta,ons	  drive	  outcome	  predominately,	  or	  are	  the	  
results	  modiﬁed	  substan,ally	  by	  gene,c	  background	  
and/or	  environment?	  i.e.	  is	  there	  really	  such	  a	  thing	  as	  
gene,c	  determinism	  for	  MANY	  muta,ons?	  
Down	  Syndrome	  
Down	  Syndrome	  
Christopher	  Joseph	  "Chris"	  Burke	  (born	  August	  
26,	  1965)	  is	  an	  American	  actor	  and	  folk	  singer,	  
who	  lives	  with	  Down	  syndrome,	  who	  has	  
become	  best	  known	  for	  his	  character	  Charles	  
"Corky"	  Thacher	  on	  the	  television	  series	  Life	  
Goes	  On.	  
	  
And	  there	  are	  people	  with	  Mosaic	  Down	  
Syndrome,	  who	  are	  much	  less	  aﬀected.	  
Velocardiofacial	  (22q11.2)	  Syndrome	  
16p11.2 deletion 
Fernandez B A et al. J Med Genet 2010;47:195-203 
©2010 by BMJ Publishing Group Ltd 
Clinical photographs. (a and b) Proband 2 (de novo deletion 16p11.2). Note long 
narrow palpebral fissures, short delicate nose, short neck and brachydactyly with 
2–3 cutaneous toe syndactyly. (c and d) Mother of proband 3 (both with 
deletions). Note her large ears, smooth philtrum and short fifth toes. 	  
16p11.2 duplication 
Fernandez B A et al. J Med Genet 2010;47:195-203 
©2010 by BMJ Publishing Group Ltd 
Clinical photographs. (e) Proband 5 who has a maternally inherited 
duplication. (f) Proband 5 (note smooth philtrum) and her healthy duplication 
positive sister. (g) Duplication positive mother of proband 5, who also has a 
smooth philtrum. (h) Proband 6 (inherited duplication and oliogohydramnios 
sequence). Note her frontal bossing, receding hairline, hypoplastic 
supraorbital ridges and smooth philtrum. (i) Proband 6's right hand showing 
fifth finger clinodactyly. 	  
16p11.2	  dele,on,	  not	  in	  mother	  or	  
father,	  only	  in	  child.	  	  
5	  years	  old,	  but	  developmental	  
age	  of	  2	  year	  old.	  
Speaks	  a	  few	  words,	  almost	  
unintelligible.	  
Very	  hyperac,ve.	  
Can	  be	  withdrawn	  and	  has	  at	  
,mes	  been	  diagnosed	  with	  
“au,sm”.	  
*Private	  Photograph	  –	  Do	  not	  further	  distribute.	  

Laurence-­‐Moon	  Syndrome,	  now	  known	  as	  Bardet-­‐Biedl	  Syndrome	  
Published	  in	  “John	  Langdon	  Down:	  A	  Caring	  Pioneer”,	  by	  O	  Conor	  Ward,	  1998.	  
Master	  Craqsman	  
Most	  famously	  designed	  The	  Great	  
Eastern,	  a	  10	  foot	  long	  model	  ship	  
with	  incredible	  detail.	  
	  
Deaf	  and	  nearly	  mute	  –	  Nonverbal,	  
Obsessed	  with	  one	  topic	  of	  
building	  things.	  
Thought	  to	  be	  mentally	  retarded.	  
Usually	  quiet	  and	  reserved,	  but	  
some,mes	  was	  intolerant	  of	  
advice,	  suspicious	  of	  strangers,	  and	  
ill-­‐tempered	  and	  violent.	  
“The	  clinical	  and	  pathological	  
evidence	  of	  a	  pervasive	  
developmental	  disorder	  points	  to	  a	  
retrospec,ve	  diagnosis	  of	  au,sm.”	  
Historical 
The Victorian genius of Earlswood - a 
review of the case of James Henry Pullen 
Caoimhghin S Breathnach, Conor Ward 
Summary 
London born James Henry Pullen (1836-1915) was 
admitted to Essex Hall in Colchester, an institution catering 
for learning disability, at the age of 13. Here his artistic 
talent was spotted before he moved two years later to 
Earlswood Asylum for Idiots, where he was apprenticed to 
woodworking. Such was his manual skill he was eventually 
employed making furniture for the asylum. His artistic 
propensity was similarly encouraged and although he never 
mastered coherent speech he has left a pictorial 
autobiography of some distinction. At observation he 
underwent detailed examination by Frederich Sano (1871-
1946), particular attention being paid to tokens of arrested 
development. The clinical and pathological evidence of a 
pervasive developmental disorder points to a retrospective 
diagnosis of autism. 
Key words: History; Autism; Victorian genius; Learning 
disability; Developmental disorder. 
Introduction 
In 1870 Sequin described children who had 'a useless 
protrusion of a single faculty accompanied by a woeful 
general impotence'.' Langdon Down introduced the term 
idiots savants to describe them.' The first idiot savant recog-
nised in England was Jedediah Buxton, an illiterate 
Derbyshire farmhand who could multiply two 39 digit 
numbers.3 Of the seven cases described by Langdon Down, 
the best known was James Henry Pullen, known colloquially 
as the Genius of Earlswood. Langdon Down's identification 
of the syndrome had previously been referred to in 1865.' 
Clinical history 
Pullen's parents were first cousins. They lived in Peckham 
in south London. Of 13 children six died in infancy and only 
three survived into adult life.' His brother William too, also 
cared for in an institution, had exceptional artistic skills. James 
Henry combined primitive speech with sign language. He 
could not write in coherent sentences, but he drew over 80 
sketches illustrating his life. These present a unique life story. 
Boats fascinated him from an early age. Wearing skirts, and 
not yet in breeches, he is seen at the age of nine years 
making a crude model ship from a wooden box. (Figure 1, left 
*Caoimhghin 5 Breathnach, MD, PhD, 
Con or Ward, MD, PhD, FRCPl, Departments of Anatomy & 
Physiology, Paediatrics and Maurice Kennedy Research Centre 
for Emeritus Staff, NUl University College Dublin, Ireland. 
*Correspondence 
SUBMlTIED: MARCH 11, 2005. ACCEPTED: OCTOBER 20. 2005. 
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pane1. Boys usually graduated to wearing breeches at the 
age of six years. Assuming that he inscribed the correct date 
his being still unbreeched at this late age suggests that he 
was seen in the family to have failed to reach an appropriate 
developmental age. The next year he watches an adult, 
maybe his father, sailing a crude three-masted sailing ship -
possibly his improved design- in a pond (Figure 1, middle 
pane1. When he was 12 he visited London. To him it was not 
a city of roads and shops and carriages but a great waterway 
alive with sailing activity (Figure 1, right pane1. In 1901 his 
sister, Mrs Earwicker, set out her memory of his early life. His 
first word was 'muvver'. No school would take him because 
he seemed to be unable to learn. He spent his time at home 
making ships from firewood, cotton and pins. In 1848, aged 
13, he was admitted to Essex Hall in Colchester, an institu-
tion catering for learning disability.' 
Essex Hall which later became the Royal Eastern Counties 
Asylum, was a charity set up by Rev Andrew Reed. It was 
here that his artistic talent was uncovered. In his pictorial 
autobiography he shows himself in 1848 drawing at a school 
table. There is no other young person in the picture, suggest-
ing that he was being taught on his own outside school hours 
(Figure 2, left pane1. The time on the clock is 1.45, school 
finished at 1.00. On this assumption the benign female pres-
ence is likely to be that of Mrs Sarah Pearce, identified in the 
Census of 1851 as the 38-year-old schoolmistress. Was it 
she who opened up new artistic horizons for him? The follow-
ing year, by which time he had learned to write his surname, 
he went on the Essex Hall outing to Walton-on-the-Naze. He 
portrayed a man leading the way towards the harbour. The 
masts of a ship stand out over the promenade wall. Mrs 
Pearce's husband Henry, a porter aged 40, may have been 
his guide. 
In 1850 James was moved to the Earlswood Asylum for 
Idiots, another institution set up by Andrew Reed. The Essex 
Hall educational programme had been very progressive,' and 
the young man portrays himself looking sadly back at Essex 
Hall and at his collection of 1 2 pictures, three of them depict-
ing boats (Figure 2, middle pane1. The configuration of the 
window does not match the shape of the windows in a 
contemporary sketch of Essex hall, suggesting that his work 
had been put on display in another location. 
He was put into the school at Earlswood, but his self-
portrait of 1851 is of a boy with his head buried in the tearful 
despair of failure (Figure 2, right pane1. By 1852, however, 
he was apprenticed to woodwork and boatmaking, and at his 
second attempt he produced a three-masted ship which he 
thought good enough to present to his teacher as a mark of 
appreciation (Figure 3, left pane1. His apprenticeship to 
woodworking led to the progressive complexity of his model-
ling especially after 1859. John Langdon Down, the newly 
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Sibling	  Defense	  Theory	  
•  Defense	  or	  modiﬁer	  Genes?	  –	  muta,ons	  that	  
somehow	  protect	  against	  or	  modify	  the	  eﬀects	  
of	  a	  primary	  muta,on.	  
•  Or,	  can	  female	  gender	  also	  somehow	  be	  
protec,ve	  with	  certain	  muta,ons?	  
•  Henry	  Pullen	  was	  one	  of	  13	  children,	  but	  only	  
3	  lived	  to	  adult	  life.	  His	  brother,	  William,	  was	  
also	  ins,tu,onalized	  and	  had	  excep,onal	  
ar,s,c	  skills.	  Their	  parents	  were	  ﬁrst	  cousins.	  
=ASD	  
=Odd,	  poten,al	  
broader	  
phenotype	  
*Private	  Photographs	  –	  Do	  not	  further	  distribute.	  
=ADHD	  =ASD	  
=Odd,	  poten,al	  
broader	  
phenotype	  
*Private	  Photographs	  –	  Do	  not	  further	  distribute.	  
New	  Syndrome	  with	  Mental	  
Retarda,on,	  “Au,sm”,	  “ADHD”	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old
	  	  
Dysmorphic	  
Mental	  Retarda,on	  
“au,sm”	  
“ADHD”	  
Hearing	  diﬃcul,es	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  gene,c	  tests	  nega,ve,	  including	  
nega,ve	  for	  Fragile	  X	  and	  MANY	  candidate	  
genes.	  
•  Found	  one	  missense	  muta,on	  in	  a	  known	  
mental	  retarda,on	  gene,	  but	  the	  muta,on	  is	  a	  
very	  conserva,ve	  nonsynonymous	  Asp	  to	  Glu.	  
Is	  it	  relevant	  or	  not?	  What	  about	  the	  whole	  
rest	  of	  the	  genome?	  
Sequenced	  whole	  genomes	  of	  Mother,	  Father	  
and	  Two	  Boys,	  using	  Complete	  Genomics	  
•  Sequenced	  “whole”	  genomes	  to	  obtain	  high-­‐
quality	  exomes	  and	  noncoding	  and	  other	  non-­‐
exonic	  regions.	  
	  
	  
Complete	  Genomics	  chemistry	  -­‐	  combinatorial	  
probe	  anchor	  liga,on	  (cPAL)	  
homozygous reference criteria are considered not called. 
Genome-Genome-Genome comparisons are performed 
using CGATM Tools v1.512 calldiff, snpdiff, and testvariants 
methods, which take into account complex variants (for 
example, loci with a SNP on one allele and a substitution 
on another) and called versus no-called sites.
Call rate and coverage: Call rate and coverage data 
are averaged over all shipments from Q3 2011 to Q1 
2012. Call rate and coverage are both measured relative 
to the 2.85GB Build 37 reference genome (excluding 
random contigs). Exome call rates are from Q1 2012 and 
are relative to RefSeq 37.2 gene models. They are up 
from the 2011 exome call rates, which averaged 95%-
96%.
There are many ways to measure coverage. Complete 
Genomics uses the gross mapped coverage (single 
and paired, unique and non-unique) from the 
coverageRefScore and summary !les11. Attributes 
of recent Complete Genomics data in the literature 
(speci!cally papers where call rate and/or coverage were 
reported) are described in Table 1. Improvements to 
call rate over time are clear from these results and have 
continued since this analysis was performed.
Trio Analysis: Called VQHIGH and homozygous 
reference sites from the YRI family trio were processed 
with the CGA Tools 1.5 listvariants and testvariants 
commands, and additional analysis was performed 
to extract MIEs. All sites fully called in the trio were 
considered, including sites called either variant or 
reference in the child. Repetitive sequences were de!ned 
using the union of the RepeatMasker, SegDup, and 
Simple Repeats tracks from the UCSC genome browser 
(genome.ucsc.edu), which collectively cover about 
53.7% of the reference genome.
Clustered MIE Analysis: The genome was segmented 
into non-overlapping windows containing 50kb of fully 
called genomic bases each, which were then sorted by 
the number of MIEs contained within each block. This 
list was then traversed until 30% of the total MIEs were 
encountered.
Technical Replicates: Two libraries independently 
constructed from NA19240 DNA were sequenced and 
analyzed. Sites called variant at VQHIGH in replicate 1 
and reference (RefScore>10) in replicate 2 were counted 
as discordant. A Bayesian statistical model was used to 
partition all discordances into putative FPs in replicate 
1 versus FNs in replicate 2 (see Reference 11, Score 
Calibration Documentation) (Table 2).
Calculation of the FP:FN tradeoff in direct 
comparisons of technical replicates: The CGA Tools 
1.5 calldiff command was used to compute the somatic 
score for each discordance between technical replicates. 
Sites called heterozygous or homozygous at a variant in 
replicate 1, and reference (for both alleles) in replicate 2, 
were counted as discordant. 
False Positive Rate: 2009 data were published in 
Reference 2. 2010 data were published in Reference 5, 
see Table 3.
Ti/Tv analysis: See References 7 and 8. Ti/Tv is 
reported for all genomes delivered from Q3 2011 to 
Q1 2012. The Ti/TV ratios in the 69 publicly available 
Complete Genomics genomes are in the same range. 
FALSE POSITIVES EST FPs FALSE NEGATIVES TOTAL DISCORDANCES CONCORDANCE
Discordant SNVs per called MB 1.56 x 10-6 4,450 1.67 x 10-6 3.23 x 10-6 99.9997% of bases
Table 2. Concordance of Technical Replicates.
COMPLETE GENOMICS CALL
OTHER PLATFORM PLATFORM-
SPECIFIC SNVs
VALIDATION RATE EST FPs FPR
Het or Hom SNV No SNV Reported 99K 17/18 = 94.4% 5,577 0.16%
No-call or Hom-Ref SNV Reported 345K 2/15 = 13.3% 299,115 8.2%
Table 3. False Positive Rate.
5
Accuracy of Complete Genomics Whole 
Human Genome Sequencing Data
Analysis Pipeline v2.0
High accuracy is critical to the effective use of whole genome sequencing (WGS) data 
by researchers and clinicians alike. Given the size of the human genome, even a small 
error rate can lead to a large total number of errors. Complete Genomics understands 
the importance of accuracy in WGS and we strive to deliver the most accurate data 
to our customers. We describe here some of the key factors to consider in measuring 
accuracy and provide an accuracy analysis for our Analysis Pipeline v2.0.
The accuracy of WGS data can be measured by a wide variety of methods, none of 
which is perfect, but many of which are informative for practical use. At the same time, 
accuracy estimates can be slanted to appear better or worse than they are; thus it is 
important that the detailed methods of their calculation be considered along with the 
results.
Techniques to improve variant detection accuracy include read and SNP !ltering 
or increasing call stringency1, but their use leads to a signi!cant and often poorly 
measured cost to sensitivity. Reports in the scienti!c literature show that Complete 
Genomics WGS, which avoids such coarse !ltering approaches, not only produces the 
lowest error rates but also does so at the highest call rates.
Complete Genomics’ approach to WGS is described below along with some 
suggestions on what to look for in measuring and comparing the accuracy of different 
sequencing approaches.
Result
Coverage and Call Rate: A key to Complete Genomics’ approach to WGS is deep 
sequencing. Complete Genomics has delivered more than 55x average gross coverage 
for all customer genomes shipped since the launch of its service. Complete Genomics 
applies an advanced bioinformatics pipeline using local de novo assembly to generate 
all small variant calls2,3, and using these methods currently achieves mean genome-
wid  call rat s of more than 97%, while call rat s in coding regions currently average 
gr ater th n 98%. These results are corroborated by rec nt reports of Complete 
Genomics’ data in the scienti!c literature (see Table 1 below).
WHITE PAPER
Analyzing	  Variants	  with	  Omicia	  Opal	  
System	  
Analyzed	  Data	  with	  Many	  Methods	  
•  No	  obvious	  pathogenic	  CNVs	  –	  microarrays	  
normal.	  
•  ~6	  million	  variants	  total	  in	  the	  4	  people	  diﬀerent	  
from	  Hg19	  reference	  genome.	  
•  No	  homozygous	  autosomal	  recessive	  muta,ons	  
found.	  
•  No	  Nonsense/Frameshiq	  muta,ons	  in	  both	  boys.	  
•  2	  muta,ons	  present	  in	  mother	  and	  two	  boys,	  on	  
X-­‐chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  
not	  in	  1000Genomes	  April	  2012	  release,	  and	  not	  
in	  NHLBI	  6500	  Exomes	  
2	  muta,ons	  present	  in	  mother	  and	  two	  boys,	  on	  
X-­‐chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  
not	  in	  1000Genomes	  April	  2012	  release,	  and	  not	  
in	  NHLBI	  6500	  Exomes	  
	  
•  Nonsyn	  SNV	  	  	  ZNF41	  	  	  	  c.1191C>A	  	  p.Asp397Glu	  	  
	  	  
•  Nonsyn	  SNV	  	  	  TAF1	  	  	  	  	  	  	  c.4010T>C	  	  p.Ile1337Thr	  	  
	  
TAF1	  RNA	  polymerase	  II,	  TATA	  box	  binding	  protein	  
(TBP)-­‐associated	  factor,	  250kDa	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Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Menzel,1 Udo Trautmann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
Claude Moraine,6 Jean-Pierre Fryns,7 Jamel Chelly,8 Hans-Dieter Rott,2 Hans-Hilger Ropers,1
and Vera M. Kalscheuer1
1Max-Planck-Institute for Molecular Genetics, Berlin; 2Institute of Human Genetics, University of Erlangen-Nuremberg, Erlangen-Nuremberg;
3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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dation” (MR), affects an estimated 2%–3% of the popu-
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tigations have highlighted the importance of genetic fac-
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
•  KRAB	  (Kruppel-­‐associated	  box)	  domain	  -­‐A	  box.	  
•  The	  KRAB	  domain	  is	  a	  transcrip,on	  repression	  module,	  found	  
in	  a	  subgroup	  of	  the	  zinc	  ﬁnger	  proteins	  (ZFPs)	  of	  the	  C2H2	  
family,	  KRAB-­‐ZFPs.	  KRAB-­‐ZFPs	  comprise	  the	  largest	  group	  of	  
transcrip,onal	  regulators	  in	  mammals,	  and	  are	  only	  found	  in	  
tetrapods.	  	  
•  The	  KRAB	  domain	  is	  a	  protein-­‐protein	  interac,on	  module	  
which	  represses	  transcrip,on	  through	  recrui,ng	  corepressors.	  
The	  KAP1/	  KRAB-­‐AFP	  complex	  in	  turn	  recruits	  the	  
heterochroma,n	  protein	  1	  (HP1)	  family,	  and	  other	  chroma,n	  
modula,ng	  proteins,	  leading	  to	  transcrip,onal	  repression	  
through	  heterochroma,n	  forma,on.	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Figure 4 A, Pedigree of family P13, with sequence corresponding to the prolinerleucinemutation (left to right): unrelated control individual,
mother (II:1), index patient (III:2), and brother of the index patient (III:1). For the potentially affected female cousin (individual III-4) (indicated
with an asterisk [*]), no clinical data are available. Affected nucleotides are indicated with black arrows. B, Pedigree for family P42, with
sequence chromatograms indicating the splice-site mutation in affected individuals (left to right): father (I:1), mother (I:2), index patient (II:1),
and mildly affected sister (II:2). Uppercase letters indicate coding sequence; affected nucleotides are indicated with black arrows.
a diagnosis of mild MR. He was born at term (by Ce-
sarean section), with a birth weight of 3,000 g (10th–25th
percentile) and a length of 51 cm (50th percentile). He
walked at age 12–13 mo and reached early milestones
within the normal time frame; however, he exhibited a
severe language delay. He first made two-word associa-
tions at age 3 years and was first speaking in simple
phrases at age 4 years 6 mo. At age 8 years, he was 135
cm tall (90th percentile) and had a head circumference
of 53 cm (75th percentile). He had no additional dys-
morphic or neurological symptoms, and results of
screening for fragile X were negative. At age 10 years 3
1350 Am. J. Hum. Genet. 73:1341–1354, 2003
Figure 6 Northern blot hybridization of ZNF41, by use of a probe corresponding to nucleotides 621–1099 of ZNF41 transcript variant
1. A, Adult tissues (left to right): heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. B, Fetal tissues (left to right): brain,
lung, liver, and kidney.C,Adult brain structures (left to right): amygdala, caudate nucleus, corpus callosum, hippocampus, whole brain, substantia
nigra, and thalamus. Black arrowheads highlight the presence of a novel 6-kb transcript. Actin (A and C) or GAPDH (B) served as controls
for RNA loading.
sible for sequence-specific DNA binding. ZNF41, absent
in our patient, is a member of the subfamily of Krueppel-
type zinc-finger proteins harboring a highly conservedN-
terminal domain known as the Krueppel-associated box
(KRAB). Although the specific functions of ZNF41 are
not fully understood, various related genes play an es-
tablished and important role in human development and
disease (Ladomery and Dellaire 2002). In another female
patient with severe MRX and a balanced translocation,
the disorder probably resulted from the disruption of a
related X-chromosomal zinc-finger gene (Lossi et al.
2002). The X-chromosome breakpoint was located just
upstream of the Krueppel-like factor 8 (KLF8 [MIM
300286]), also known as the “ZNF741 gene,” and it was
confirmed that KLF8 transcripts were absent in the pa-
tient cell line. The Wilms tumor suppressor gene WT1
(MIM 194070), which harbors four Krueppel-type zinc
fingers, has been implicated in several urogenital devel-
opmental disorders, including WAGR syndrome (MIM
194072), which is associated with MR (Call et al. 1990;
Rose et al. 1990; Gessler et al. 1992). Of particular rel-
evance, however, are the biochemical studies that high-
light the links between the highly conserved KRAB/ZFP
subfamily of zinc-finger proteins and chromatin remod-
eling. Many disorders, several of which are associated
with MR, have been linked to defects in processes that
govern chromatin structural modification (Hendrich and
Bickmore 2001), suggesting that chromatin structural
regulationmay play a specific and important role in path-
ways critical for mental function.
Repression of transcription by a KRAB/ZFP requires
binding of the corepressor KAP-1 (also known as
“TIF1b” and “KRIP-1” [MIM 601742]) (Friedman et
al. 1996; Kim et al. 1996; Moosmann et al. 1996; Peng
et al. 2000a, 2000b). KAP-1 is a molecular scaffold that
coordinates gene-specific silencing by recruiting both
heterochromatin-associated proteins (Ryan et al. 1999)
and by interacting with the novel histone H3 Lys9–
specific methyltransferase SETDB1 (MIM 604396)
(Schultz et al. 2002). It is interesting that, within the
primary sequence of SETDB1, Schultz et al. (2002) iden-
tified a methyl CpG–binding domain that is related to
the domain found in the methyl CpG binding protein
MeCP2, which is mutated both in patients with Rett
syndrome (MIM 312750) (Amir et al. 1999) and in
patients with MRX (Couvert et al. 2001; Yntema et al.
2002). Like ZNF41, MECP2 is ubiquitously expressed;
yet loss of functional protein results in a neurological
phenotype. Although the mechanism by whichMECP2
mutations cause MR is not clear, it is well established
that MeCP2 binds to methylated CpGs and represses
transcription (for review, see Ballestar and Wolffe
[2001]), and it has recently been shown that MeCP2
associates with an unidentified methyltransferase that
specifically methylates Lys9 of histone H3 (Fuks et al.
2003), as does the KAP-1/KRAB/ZFP binding partner
SETDB1.
Further characterization of the KRAB/KAP-1 repres-
sor module has indicated that, in addition to the KRAB
domain, a bipartite domain of the plant homeodomain
(PHD) finger and a bromodomain, located within the C-
terminal portion of KAP-1, are also required for effective
gene silencing (Schultz et al. 2002). It is interesting that
the point mutations in that study were modeled after
naturally occurring mutations in the PHD finger of the
human ATRX gene, which has been implicated in both
X-linked a-thalassemia/MR syndrome (MIM 301040)
(Gibbons et al. 1995) and Juberg-Marsidi syndrome
(MIM 309590), which is also associated with MR (Vil-
lard et al. 1996a). In light of the fact that the PHD
Proving	  Causality	  
•  Will	  need	  to	  ﬁnd	  a	  second,	  unrelated	  family	  with	  same	  exact	  mu a,on	  and	  
similar	  phenotype.	  
•  Can	  also	  p rform	  in	  vitro/in	  vivo	  studies	  an 	  struct ral	  mod ling,	  and	  make	  
knock-­‐in	  mice	  and/or	  test	  in	  zebraﬁsh,	  etc…	  for	  biological	  func,on.	  
•  But	  how	  I	  am	  going	  to	  ﬁnd	  a	  second	  family	  
with	  this	  same	  muta,on	  and	  same	  
phenotype?	  
Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked	  for	  thousands	  of	  
volunteer	  families.	  
Pa=entsLikeMe	  

Major	  Barriers	  to	  the	  implementa,on	  of	  
Genomic	  Medicine	  in	  the	  clinic:	  
1)  Lack	  of	  public	  educa,on	  –	  consumer	  not	  sure	  it	  macers.	  
2)  Lack	  of	  physician	  knowledge	  about	  gene,cs.	  
3)  Apathy	  on	  the	  part	  of	  populace,	  as	  they	  have	  been	  lulled	  into	  
being	  apathe,c	  and	  not	  empowered	  about	  their	  own	  health.	  
4)  Refusal	  of	  insurance	  companies	  to	  pay	  for	  “not	  useful”	  
gene,c	  tes,ng.	  
5)  Focus	  in	  our	  society	  on	  Treatment,	  NOT	  on	  early	  diagnosis	  
and	  preven,on.	  
Emphasis	  Should	  be	  on	  Diagnosis	  and	  
Preven,on,	  NOT	  just	  on	  Treatment	  
•  15	  year	  old	  girl	  with	  Type	  I	  diabetes,	  hospitalized	  
dozens	  of	  ,mes	  with	  diabe,c	  ketoacidosis.	  
Millions	  spent	  to	  save	  life	  repeatedly,	  but	  very	  
licle	  on	  therapy	  or	  educa,on	  –	  WHY?	  
•  14	  year	  old	  boy	  hospitalized	  >10	  ,mes	  with	  
pancrea,,s	  over	  >	  ten	  years.	  Finally,	  someone	  
gets	  gene,cs	  consult.	  Pa,ent	  has	  cys,c	  ﬁbrosis,	  
undiagnosed	  ,ll	  then.	  Beneﬁts	  from	  pancrea,c	  
enzyme	  supplementa,on,	  plus	  therapy	  and	  
educa,on.	  WHY	  so	  LONG	  to	  diagnose?	  
I	  would	  suggest	  that	  researchers	  working	  on	  
DNA	  samples	  from	  living	  humans	  perform	  CLIA-­‐
cer,ﬁed	  sequencing	  UP	  FRONT,	  either	  with	  
exomes	  or	  whole	  genomes,	  so	  that	  we	  can	  
network	  the	  genomes	  and	  exomes	  &	  return	  
results	  to	  consumers,	  “pa,ents”,	  research	  
par,cipants	  and	  families.	  
	  
	  
	  
	  
Clinical	  grade	  exome	  and	  whole	  genome	  DNA	  tes=ng	  
should	  mean:	  
	  
1)  Blood	  or	  saliva	  collected	  with	  rigorous,	  automated	  sample	  
tracking.	  
2)  DNA	  isolated	  in	  a	  CLIA-­‐cer,ﬁed	  facility.	  
3)  Sequencing	  performed	  in	  a	  CLIA-­‐cer,ﬁed	  facility.	  
4)  Analysis	  performed	  with	  a	  CLIA-­‐cer,ﬁed	  bioinforma,cs	  pipeline.	  
	  
For	  now,	  more	  eﬀort	  should	  be	  placed	  
on	  the	  following:	  
•  Rare,	  highly	  penetrant	  muta,ons	  running	  in	  families,	  
with	  cascade	  carrier	  tes,ng.	  
•  The	  genomic	  background	  is	  much	  more	  constant	  in	  
families.	  
•  The	  environmental	  background	  is	  some,mes	  more	  
constant	  in	  families.	  
•  This	  allows	  one	  to	  know	  much	  more	  about	  issues	  with	  
penetrance	  of	  rare	  variants	  in	  these	  families.	  
An	  alternate	  universe	  
•  Genomes	  sequenced	  by	  companies	  and	  academics	  with	  the	  
minimal	  standards	  in	  place	  (i.e.	  CLIA	  in	  America).	  
•  All	  data,	  including	  variant	  lists,	  added	  to	  “the	  cloud”	  that	  
consumers	  can	  access.	  
•  Consumers	  can	  go	  back	  and	  repeatedly	  look	  at	  their	  own	  
genome.	  
•  Consumers	  own	  and	  manage	  these	  data,	  and	  they	  can	  pay	  
anyone	  they	  like	  to	  help	  them	  interpret	  the	  data	  with	  them.	  
•  These	  are	  CONSUMERS,	  not	  pa,ents,	  and	  we	  need	  to	  move	  
away	  from	  paternalis=c	  medicine.	  
•  I	  am	  concerned	  that	  regula,on	  requiring	  delivery	  of	  gene,c	  
data	  by	  “physicians”	  will	  choke	  oﬀ	  and	  kill	  the	  genomic	  
revolu,on	  and	  individualized	  medicine.	  
One	  Solu,on	  
•  I	  pray	  and	  hope	  that	  we	  will	  move	  toward	  colla,ng	  
and	  distribu,ng	  muta,ons	  in	  an	  interna,onal	  
human	  varia,on	  database,	  allowing	  for	  calcula,on	  
of	  penetrance	  and	  extensive	  burden	  tes,ng.	  
•  CLIA-­‐cer,ﬁed	  (clinical	  grade)	  sequencing	  up	  front	  
allows	  return	  of	  all	  data,	  including	  rare,	  highly	  
penetrant	  muta,ons,	  to	  families,	  facilita,ng	  carrier	  
screening	  and	  counseling.	  
•  Require	  return	  of	  genomic	  data	  to	  par,cipants,	  
allowing	  the	  par,cipants	  to	  distribute	  and	  “crowd-­‐
source”	  their	  own	  data.	  
•  Government	  should	  divert	  funds	  toward	  a	  10	  to	  
100	  fold	  increase	  for	  gene,c	  counselors,	  so	  that	  we	  
can	  have	  compassionate	  engagement	  with	  families.	  
Ancestry.com	  meets	  23andMe	  meets	  
Pa,entsLikeMe	  meets	  WGS?	  
Clinical	  Validity	  with	  Worldwide	  
Human	  Gene,c	  Varia,on	  “database”?	  
Pa=entsLikeMe	  
Figure 4.	

	

Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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•  END	  OF	  THE	  TALK	  
•  EXTRA	  SLIDES	  NEXT	  
“The	  fundamental	  mistake	  which	  vi,ates	  all	  work	  based	  
upon	  Mendel’s	  method	  is	  the	  neglect	  of	  ancestry,	  and	  the	  
acempt	  to	  regard	  the	  whole	  eﬀect	  upon	  oﬀspring,	  
produced	  by	  a	  par,cular	  parent,	  as	  due	  to	  the	  existence	  
in	  the	  parent	  of	  par,cular	  structural	  characters;	  while	  the	  
contradictory	  results	  obtained	  by	  those	  who	  have	  
observed	  the	  oﬀspring	  of	  parents	  apparently	  iden,cal	  in	  
certain	  characters	  show	  clearly	  enough	  that	  not	  only	  the	  
parents	  themselves,	  but	  their	  race,	  that	  is	  their	  ancestry,	  
must	  be	  taken	  into	  account	  before	  the	  result	  of	  pairing	  
them	  can	  be	  predicted.”	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“Biological	  Indeterminacy”	  
•  Bateson	  became	  famous	  as	  the	  outspoken	  
Mendelian	  antagonist	  of	  Walter	  Raphael	  Weldon,	  
his	  former	  teacher,	  and	  Karl	  Pearson	  who	  led	  the	  
biometric	  school	  of	  thinking.	  This	  concerned	  the	  
debate	  over	  salta,onism	  versus	  gradualism	  
(Darwin	  had	  been	  a	  gradualist,	  but	  Bateson	  was	  a	  
salta,onist).	  Later,	  Ronald	  Fisher	  and	  
J.B.S.	  Haldane	  showed	  that	  discrete	  muta,ons	  
were	  compa,ble	  with	  gradual	  evolu,on:	  see	  the	  
modern	  evolu,onary	  synthesis.	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